PROMETHERA Biosciences S.A./N.V. To Present At The 2016 Cell & Gene Meeting On The Mesa
Mont-Saint-Guibert, Belgium, September 29, 2016 – Promethera Biosciences SA, a Belgian biotechnology company with U.S. operations developing cell therapies treating a broad range of liver diseases with high unmet medical needs, today announces that Dr. Torsten Hombeck, Chief Commercial & Strategy Officer, Promethera, will present at the Cell & Gene Meeting on the Mesa. The event will be on October 5-7 in La Jolla, California, US.
The presentation will be held at 4.30pm PST on October 6, 2016. It will include an update on Promethera’s research and development pipeline as well as the strategy and corporate goals following Promethera’s recent acquisition of key assets of Cytonet, the international cellular therapy company involving primary human hepatocytes. This transaction has made Promethera the world’s leading and most advanced cell therapy and regenerative medicine company targeting a broad range of liver diseases.
“Promethera continues its strategy to build the most advanced company in the field of stem cell therapies for the treatment of inborn liver metabolic diseases and acquired liver diseases,” said Dr. Torsten Hombeck, Chief Commercial & Strategy Officer, Promethera Biosciences, “It is important for Promethera to share the current advances and experiences on new cell based treatment approaches to these pathologies to the benefit of the entire cell therapy community. The Partnering Forum at The Cell & Gene Meeting on the Mesa provides an excellent opportunity to present both the latest Promethera corporate and scientific developments.”
Organized by the Alliance for Regenerative Medicine (ARM) and the Sanford Consortium for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference bringing together senior executives from the cell and gene therapy and the scientific communities to discuss the most pressing issues facing the sector. A live video webcast of Torsten Hombeck’s presentation will be available at: http://www.meetingonthemesa.com/webcast/ and will also be published on ARM’s website shortly after the event.
About Promethera Biosciences
Promethera Biosciences is a clinical stage biopharmaceutical company and the global leader in cell therapy and regenerative medicine for the treatment of inborn and acquired liver diseases with no effective therapeutic cure.
Promethera uses allogeneic
progenitor cells, stem cells and mature hepatocytes that are harvested and purified from non-transplantable, healthy human livers (Heterologous Human Adult Liver-derived Progenitor Cells, HHALPC and Heterologous Human Liver Cells, HHLivC). These technologies have resulted in the development of three different cell products, HepaStem and H2Stem (progenitor/stem cells) and Heparesc(R) (mature hepatocytes). Promethera specializes in the development of therapeutic options for the treatment of a broad variety of liver diseases. These range from orphan indications, such as rare inborn metabolic diseases including urea cycle disorders (UCD) or inherited diseases such as a1at deficiency (a1-antitrypsin) and hemophilia to large indications such as acute on chronic liver failure (ACLF), fibrosis and nonalcoholic steatohepatits (NASH).
Promethera Biosciences is a spin-off of the Walloon Region-based Université catholique de Louvain (UCL) and was founded in 2009 by Prof. Dr. Etienne Sokal and Sopartec, the tech transfer office (TTO) of UCL. Promethera is headquartered in Mont-Saint-Guibert, Belgium with a U.S. based GMP compliant manufacturing facility in Durham, NC, US. For more information, visit www.promethera.com.
The presentation will be held at 4.30pm PST on October 6, 2016. It will include an update on Promethera’s research and development pipeline as well as the strategy and corporate goals following Promethera’s recent acquisition of key assets of Cytonet, the international cellular therapy company involving primary human hepatocytes. This transaction has made Promethera the world’s leading and most advanced cell therapy and regenerative medicine company targeting a broad range of liver diseases.
“Promethera continues its strategy to build the most advanced company in the field of stem cell therapies for the treatment of inborn liver metabolic diseases and acquired liver diseases,” said Dr. Torsten Hombeck, Chief Commercial & Strategy Officer, Promethera Biosciences, “It is important for Promethera to share the current advances and experiences on new cell based treatment approaches to these pathologies to the benefit of the entire cell therapy community. The Partnering Forum at The Cell & Gene Meeting on the Mesa provides an excellent opportunity to present both the latest Promethera corporate and scientific developments.”
Organized by the Alliance for Regenerative Medicine (ARM) and the Sanford Consortium for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference bringing together senior executives from the cell and gene therapy and the scientific communities to discuss the most pressing issues facing the sector. A live video webcast of Torsten Hombeck’s presentation will be available at: http://www.meetingonthemesa.com/webcast/ and will also be published on ARM’s website shortly after the event.
About Promethera Biosciences
Promethera Biosciences is a clinical stage biopharmaceutical company and the global leader in cell therapy and regenerative medicine for the treatment of inborn and acquired liver diseases with no effective therapeutic cure.
Promethera uses allogeneic
progenitor cells, stem cells and mature hepatocytes that are harvested and purified from non-transplantable, healthy human livers (Heterologous Human Adult Liver-derived Progenitor Cells, HHALPC and Heterologous Human Liver Cells, HHLivC). These technologies have resulted in the development of three different cell products, HepaStem and H2Stem (progenitor/stem cells) and Heparesc(R) (mature hepatocytes). Promethera specializes in the development of therapeutic options for the treatment of a broad variety of liver diseases. These range from orphan indications, such as rare inborn metabolic diseases including urea cycle disorders (UCD) or inherited diseases such as a1at deficiency (a1-antitrypsin) and hemophilia to large indications such as acute on chronic liver failure (ACLF), fibrosis and nonalcoholic steatohepatits (NASH).
Promethera Biosciences is a spin-off of the Walloon Region-based Université catholique de Louvain (UCL) and was founded in 2009 by Prof. Dr. Etienne Sokal and Sopartec, the tech transfer office (TTO) of UCL. Promethera is headquartered in Mont-Saint-Guibert, Belgium with a U.S. based GMP compliant manufacturing facility in Durham, NC, US. For more information, visit www.promethera.com.